Is There A Better Way To Secure Stable Funding For Medical Research?

For Medical Research? The 5.7 percent increase in the National Institutes of Health's appropriation for fiscal 1996 represents startling bipartisan support by the House, the Senate, and President Clinton. The $11.94 billion total appropriation, greater than the president's original request, is $640 million over the 1995 funding level. The increase was made possible largely by a Republican Congress otherwise zealous about controlling the debt and the deficit. But let's look this gift horse in t

Written byLorraine Lasker
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

For Medical Research? The 5.7 percent increase in the National Institutes of Health's appropriation for fiscal 1996 represents startling bipartisan support by the House, the Senate, and President Clinton.

The $11.94 billion total appropriation, greater than the president's original request, is $640 million over the 1995 funding level. The increase was made possible largely by a Republican Congress otherwise zealous about controlling the debt and the deficit. But let's look this gift horse in the mouth. The NIH budget success is not without ambiguity, irony, and uncertainty. Is there a better way to secure funding?

Adequate funding for investigator-initiated proposals judged "outstanding" and "excellent" by scientific peers requires a stable, vigorous research enterprise, which cannot thrive with an uncertain, annual appropriation. The ideal, however, may be realizable-sans new taxes-through voluntary contribution. The Internal Revenue Service code could cast the net to secure the catch.

The FY 1996 NIH appropriation was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies